These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 10945636)
1. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Wurzer G; Herceg Z; Wesierska-Gadek J Cancer Res; 2000 Aug; 60(15):4238-44. PubMed ID: 10945636 [TBL] [Abstract][Full Text] [Related]
2. Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828. Wojciechowski J; Lövborg H; Wesierska-Gadek J Drugs Exp Clin Res; 2003; 29(2):53-67. PubMed ID: 12951835 [TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Wesierska-Gadek J; Schmid G Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635 [TBL] [Abstract][Full Text] [Related]
4. Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1. Lövborg H; Wojciechowski J; Larsson R; Wesierska-Gadek J Cancer Res; 2002 Aug; 62(15):4206-11. PubMed ID: 12154020 [TBL] [Abstract][Full Text] [Related]
5. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Wesierska-Gadek J; Wang ZQ; Schmid G Cancer Res; 1999 Jan; 59(1):28-34. PubMed ID: 9892179 [TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
7. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action. Wesierska-Gadek J J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398 [TBL] [Abstract][Full Text] [Related]
8. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675 [TBL] [Abstract][Full Text] [Related]
9. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658 [TBL] [Abstract][Full Text] [Related]
10. Ability to acquire drug resistance arises early during the tumorigenesis process. Yagüe E; Arance A; Kubitza L; O'Hare M; Jat P; Ogilvie CM; Hart IR; Higgins CF; Raguz S Cancer Res; 2007 Feb; 67(3):1130-7. PubMed ID: 17283147 [TBL] [Abstract][Full Text] [Related]
11. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
12. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608 [TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135 [TBL] [Abstract][Full Text] [Related]
14. Drug resistance in chemotherapy for breast cancer. Saeki T; Tsuruo T; Sato W; Nishikawsa K Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361 [TBL] [Abstract][Full Text] [Related]
15. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Yu ST; Chen TM; Tseng SY; Chen YH Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571 [TBL] [Abstract][Full Text] [Related]
16. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Peer D; Dekel Y; Melikhov D; Margalit R Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283 [TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Ratnasinghe D; Daschner PJ; Anver MR; Kasprzak BH; Taylor PR; Yeh GC; Tangrea JA Anticancer Res; 2001; 21(3C):2141-7. PubMed ID: 11501838 [TBL] [Abstract][Full Text] [Related]
18. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Zhang YF; Li XH; Shi YQ; Wu YY; Li N; He Q; Ji Q; Wang RQ; Yang SM; Fang DC Oncol Rep; 2011 Apr; 25(4):1091-8. PubMed ID: 21240465 [TBL] [Abstract][Full Text] [Related]
19. Reversal of cancer multidrug resistance by green tea polyphenols. Mei Y; Qian F; Wei D; Liu J J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646 [TBL] [Abstract][Full Text] [Related]
20. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]